Pharmaceutical News

RSS

AAMPS, ChromaDex sign exclusive marketing agreement for African Herbal Pharmacopoeia

ChromaDex Corporation, a world leader in phytochemical reference standards, botanical reference materials and contract analytical testing services, has signed an exclusive marketing agreement with the Association for African Medicinal Plants Standards (AAMPS) to sell and market the AAMPS African botanical standards and the African Herbal Pharmacopoeia.

30 Aug 2011

DNA sequencing pioneer, two pharmaceutical researchers recognized as ACS 'Heroes of Chemistry'

Two scientists developed a new drug that helped pioneer the era of "personalized medicine" for cancer patients, an approach in which one-size-fits-all drugs yield to medicines customized to the genetic endowment of individual patients. Another scientist invented today's predominant technology for genetic sequencing, deciphering the genetic blueprint in the DNA that makes up the genes of living things.

30 Aug 2011

Vitamin A supplements could save the lives of 600,000 children a year, researchers say

"Giving vitamin A supplements to children under the age of five in developing countries could save 600,000 lives a year, researchers claim" in a paper published Thursday in the British Medical Journal, BBC News reports.

30 Aug 2011

AstraZeneca: BRILIQUE receives Class I recommendation from ESC

AstraZeneca today announced BRILIQUE, a new oral antiplatelet medicine, received a Class I recommendation from the European Society of Cardiology (ESC) in the revised "Guidelines for Management of Acute Coronary Syndromes (ACS) in patients presenting without persistent ST-segment elevation."

30 Aug 2011

Everolimus-eluting stent reduces incidence of stent thrombosis

Results of the independently-funded Bern-Rotterdam cohort study provide robust evidence of an "important" reduction in overall and very late stent thrombosis.

30 Aug 2011

Ipsen, Inspiration partner to launch hemophilia product portfolio in Europe

Ipsen and Inspiration Biopharmaceuticals Inc. today announced they have entered into a strategic partnership agreement, to create a European hemophilia commercial organization, to launch Inspiration's hemophilia product portfolio in Europe.

30 Aug 2011

Vitamin C supplementation might benefit children with asthma

Depending on the age of asthmatic children, on their exposure to molds or dampness in their bedroom, and on the severity of their asthma, vitamin C has greater or smaller beneficial effect against asthma, according to a study published in the Clinical and Translational Allergy.

30 Aug 2011

High risk of serious complications or death in children with SP-HUS

Hemolytic uremic syndrome (HUS) caused by infection with pneumococcal bacteria leads to severe illness—with a high rate of irreversible kidney damage—in infants and young children, reports a study in the September issue of The Pediatric Infectious Disease Journal.

30 Aug 2011

Study indicates large gap in use of proven therapies for heart attack or stroke

A global study in 17 countries led by McMaster University researchers has found too few patients are using drugs proven to give significant benefits in warding off a heart attack or stroke.

30 Aug 2011

Ivabradine reduces heart volume among patients with cardiac insufficiency

As guest speaker at the European Society of Cardiology's Congress currently under way in Paris, Dr. Jean-Claude Tardif, Director of the Montreal Heart Institute's Research Centre and professor of medicine at the Universit- de Montr-al, today presented the results of an analysis demonstrating that ivabradine, a medication used to reduce heart rate, also reduces heart volume (left ventricle) among patients with cardiac insufficiency.

30 Aug 2011

Pfizer receives FDA approval of XALKORI for ALK-positive NSCLC

Pfizer Inc. has received FDA approval of XALKORI (crizotinib) capsules - the first and only therapy specifically for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

29 Aug 2011

UCLA-Harvard medication study highlights 3 types of confusing outcome measures

Studies about medications published in the most influential medical journals are frequently designed in a way that yields misleading or confusing results, new research suggests.

29 Aug 2011

Health Canada approves Bayer's STAXYN for treatment of erectile dysfunction

Today, Bayer Inc. announced the Health Canada approval of STAXYN, the first orally disintegrating tablet for the treatment of erectile dysfunction (ED) that lasts up to eight hours.

29 Aug 2011

Infrared Systems completes several internal projects, discusses corporate strategies

Infrared Systems International announces the completion of several internal projects and discusses corporate strategies for continued success.

29 Aug 2011

Researchers use metformin to effectively starve cancer cells

CANCER RESEARCH UK scientists have discovered how blocking a key controller of energy production in cancer cells and treating them with a diabetes drug, metformin, effectively starves cancer cells.

29 Aug 2011

Leucine may help people burn fat during periods of food restriction

Research on Mt. Everest climbers is adding to the evidence that an amino acid called leucine - found in foods, dietary supplements, energy bars and other products - may help people burn fat during periods of food restriction, such as climbing at high altitude, while keeping their muscle tissue.

29 Aug 2011

One in three AF patients at high risk of stroke are not being prescribed VKA therapy

New data show that, worldwide, one in three patients with atrial fibrillation (AF) who are at high risk for stroke are not being prescribed anticoagulant therapy, particularly vitamin K antagonists (VKA) – medicines known to significantly lower stroke risk in these patients.

29 Aug 2011

Pfizer's Xalkori receives FDA approval to treat late-stage NSCLC patients with abnormal ALK gene

The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers (NSCLC) who express the abnormal anaplastic lymphoma kinase (ALK) gene.

29 Aug 2011

LUNGevity Foundation applauds FDA's recent approval of XALKORI lung cancer drug

LUNGevity Foundation applauds the US Food and Drug Administration's (FDA) recent approval of XALKORI (crizotinib) to treat lung cancer. The drug, introduced by Pfizer, Inc. showed such promise in early trials that it was given "fast track" status by the FDA.

29 Aug 2011

Astellas seeks regulatory approval for mirabegron to treat overactive bladder in the U.S., Europe

Astellas Pharma Inc. today announced the submission of a New Drug Application and Market Authorisation Application for mirabegron to the U.S. Food and Drug Administration and the European Medicines Agency.

29 Aug 2011